The role of CD4+ T cell responses in antitumor immunity.

While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses, recent evidence indicates that CD4+ T cells are an equally critical component of the antitumor immune response. Successful immunity to cancer will therefore require activation of tumor-specific CD4+ T cells. Tumor antigens recognized by CD4+ T cells that are restricted by MHC class II are beginning to be defined in both murine and human tumors. These will provide the basis for new generations of antigen-specific tumor vaccines.

• Publication year

  1998

• Venue

  Current Opinion in Immunology

• Publication date

  1998-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0952-7915(98)80228-8PMID 9794842
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study.

  1998cited by this paper
• Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

  1998cited by this paper
• Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

  1998cited by this paper
• CD4+ T Cell Tolerance to Parenchymal Self-Antigens Requires Presentation by Bone Marrow–derived Antigen-presenting Cells

  1998cited by this paper
• B cells inhibit induction of T cell-dependent tumor immunity

  1998cited by this paper
• Help for cytotoxic-T-cell responses is mediated by CD40 signalling

  1998cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

  1998cited by this paper
• Dominant TCRB‐V‐J chain usage and clonal expansion of sarcoma‐reactive CD4+ HLA‐DR‐restricted T cells suggest a limited set of immunodominant sarcoma antigens

  1997cited by this paper
• Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

  1997cited by this paper
• A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy

  1997cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper
• CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

  1997cited by this paper
• Interactions between autologous CD4+ and CD8+ T lymphocytes and human squamous cell carcinoma of the head and neck.

  1997cited by this paper
• Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy

  1997cited by this paper
• HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.

  1997cited by this paper
• T cells recognize the VH complementarity‐determining region 3 of the idiotypic protein of B cell non‐Hodgkin's lymphoma

  1997cited by this paper
• Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.

  1997cited by this paper
• Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21‐ras (12VAL) peptide vaccination of a patient, recognize 12VAL‐dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

  1997cited by this paper
• The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.

  1996cited by this paper
• Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

  1996cited by this paper
• Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens.

  1996cited by this paper
• Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.

  1996cited by this paper
• Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

  1996cited by this paper
• Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.

  1995cited by this paper
• Principles for adoptive T cell therapy of human viral diseases.

  1995cited by this paper
• A unique tumor antigen produced by a single amino acid substitution.

  1995cited by this paper
• Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

  1995cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.

  1995cited by this paper
• Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.

  1995cited by this paper
• Tumor immunotherapy: the tumor cell as an antigen-presenting cell.

  1994cited by this paper
• Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

  1994cited by this paper
• In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

  1994cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.

  1994cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

  1993cited by this paper
• Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.

  1993cited by this paper
• Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.

  1992cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Interleukin 7 induces CD4+ T cell-dependent tumor rejection

  1991cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones.

  1987cited by this paper
• Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

  1985cited by this paper
• Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.

  1985cited by this paper

• RBBP8 Is a Prognostic Biomarker Associated With Response to Immune Checkpoint Inhibitors in Advanced Gastric Cancer

  2025cites this paper
• CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas

  2025cites this paper
• IL-1 family members as regulators of lymphoid type-2 immunity in cancer.

  2025cites this paper
• Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity.

  2025cites this paper
• The cGAS-STING axis: a comprehensive review from immune defense to disease pathogenesis

  2025cites this paper
• Prostaglandin D2 axis impairs immunity against melanoma via dendritic cells and γδ T cells in middle-aged mice.

  2025cites this paper
• Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma

  2025cites this paper
• Modulated electro-hyperthermia therapy combined with Korean mistletoe extract treatment exerts a strong anti-tumor activity by enhancing cellular and humoral immune responses in mice

  2025cites this paper
• Rapid monitoring of T- lymphocyte CD4+/CD8+ ratio in patient immune management by infrared spectroscopy of whole leukocytes

  2024cites this paper
• Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

  2024cites this paper
• The immune microenvironment of lung adenocarcinoma featured with ground‐glass nodules

  2024cites this paper
• Case report: Regression of in-transit metastases of cutaneous squamous cell carcinoma with combination pembrolizumab and topical diphencyprone

  2024cites this paper
• PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model

  2024cites this paper
• Current progress of immunotherapy in cancer treatment

  2024cites this paper
• Neurobiology of cancer: Adrenergic signaling and drug repurposing.

  2024cites this paper
• LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition

  2023cites this paper
• Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients

  2023cites this paper
• Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2023cites this paper
• Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.

  2023cites this paper
• Prognostic Impact of Tumor Immune Microenvironment and Its Predictive Role in Salivary Gland Cancer

  2023cites this paper
• Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA

  2023cites this paper
• Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1

  2023cites this paper
• Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study

  2023cites this paper
• Identification and Structure of Epitopes on Cashew Allergens Ana o 2 and Ana o 3 Using Phage Display

  2023cites this paper
• Analysis and Validation of the Prognosis ability of the M7G-Related miRNAs in Lung Adenocarcinoma

  2023cites this paper
• The Relationship Between Lymphocyte Subtypes with Clinicopathological Features and Prognosis of Prostate Cancer in Patients Undergoing Radical Prostatectomy

  2023cites this paper
• Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy

  2022cites this paper
• Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

  2022cites this paper
• CD4+ T cell-induced in ammatory killing controls immune evasive tumours

  2022cites this paper
• Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma

  2022cites this paper
• The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma

  2022cites this paper
• Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer

  2022cites this paper
• Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy

  2022cites this paper
• Novel antitumor therapeutic strategy using CD4+ T cell-derived extracellular vesicles.

  2022cites this paper
• Human-T-Cell-Selective Fluorescent Probe

  2022cites this paper
• Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance

  2022cites this paper
• Effects of Chemotherapy on Hematological Parameters and CD4+/CD8+ Ratio in Cats with Mediastinal Lymphoma and Seropositive to Feline Leukemia Virus

  2022cites this paper
• Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

  2022cites this paper
• Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety

  2022cites this paper
• Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

  2022cites this paper
• The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis

  2022cites this paper
• Immune checkpoint inhibition in early-stage triple-negative breast cancer

  2022cites this paper
• Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens

  2022cites this paper
• On a global continuum model for COVID-19 virus in the presence of vaccine and induced immunity. Stability and initial states control

  2022cites this paper
• Strategies and Applications for Improving the Stability of Black Phosphorus in Physical Environment

  2021cites this paper
• Prophylactic dendritic cell vaccination in antitumor immune response and tumor growth in a breast cancer mouse model

  2021cites this paper
• Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours

  2021cites this paper
• Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model

  2021cites this paper
• Prognostic Utility of Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio and Monocyte–Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta-Analysis

  2021cites this paper
• Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.

  2021cites this paper
• Lymphopenia in Esophageal Cancer: What Have We Learned?

  2021cites this paper
• Importance of particle size of oligomannose-coated liposomes for induction of Th1 immunity.

  2021cites this paper
• Interferon-gamma inhibits aldehyde dehydrogenasebright cancer stem cells in the 4T1 mouse model of breast cancer

  2021cites this paper
• Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer

  2021cites this paper
• Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B‐cell lymphoma in the North Indian population

  2021cites this paper
• Perioperative lymphocyte-to-monocyte ratio changes plus CA199 in predicting the prognosis of patients with gastric cancer.

  2021cites this paper
• Evaluation of the Immunomodulatory and Anti-Inflammatory Activities of Honey Bee Larva Powder

  2020cites this paper
• Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells

  2020cites this paper
• Cancer Cell Intrinsic Expression of MHCII Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma

  2020cites this paper
• Breast Cancer Is Associated with Increased HLA-DRB1*11:01 and HLA-DRB1*10:01 Allele Frequency in a Population of Patients from Central Italy

  2020cites this paper
• Permissive State of EMT: The Role of Immune Cell Compartment

  2020cites this paper
• Immunology of Melanoma

  2020cites this paper
• Immunopeptidome screening to design An immunogenic construct against PRAME positive breast cancer; An in silico study

  2020cites this paper
• Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies

  2020cites this paper
• Cancer Cell–Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti–PD-1 Therapy in Lung Adenocarcinoma

  2020cites this paper
• HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma.

  2020cites this paper
• Telomerase-based cancer therapeutics: a review on their clinical trials.

  2020cites this paper
• Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

  2020cites this paper
• Post-translational modifications such as citrullination are excellent targets for cancer therapy.

  2020cites this paper
• Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells

  2020cites this paper
• Obesity diminishes response to PD-1-based immunotherapies in renal cancer

  2020cites this paper
• Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy

  2020cites this paper
• Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?

  2020cites this paper
• Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

  2020cites this paper
• Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunity

  2020cites this paper
• Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment

  2020cites this paper
• Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study.

  2020cites this paper
• EZH2 inhibition: a promising strategy to prevent cancer immune editing.

  2020cites this paper
• Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell

  2020cites this paper
• Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with clinical insight.

  2020cites this paper
• Inmuno-monitoreo del componente de células presentadoras de antígeno (APC) y células T en distintos estadios del desarrollo de cáncer gástrico de tipo intestinal

  2019cites this paper
• Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.

  2019cites this paper
• Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.

  2019cites this paper
• Striking a Balance—Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation

  2019cites this paper
• Novel nucleotide variants in SLA-DOB and CD4 are associated with immune traits in pregnant sows.

  2019cites this paper
• MHC Class II tetramers and the pursuit of antigen-specific T cells : define , deviate

  2019cites this paper
• Local and Systemic Antitumor Effects of Photo‐activatable Paclitaxel Prodrug on Rat Breast Tumor Models

  2019cites this paper
• Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo

  2019cites this paper
• Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy

  2019cites this paper
• Role of the tumor microenvironment on the progression of lung cancer, The

  2019cites this paper
• Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade

  2019cites this paper
• GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses

  2019cites this paper
• Caractérisation du micro-environnement tumoral et des points de contrôle immunitaires dans les lymphomes B diffus à grandes cellules primitifs du système nerveux central : à propos d'une série de 57 cas

  2019influential citation
• Control of multilayer biological networks and applied to target identification of complex diseases

  2019cites this paper
• The identification of immune responses required for durable control of childhood acute lymphoblastic leukemia

  2019cites this paper
• Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas

  2019cites this paper
• Aging, Cancer and Immunity

  2019cites this paper
• A role of eosinophils in mediating the anti-tumour effect of cryo-thermal treatment

  2019cites this paper
• Preparation of nanoliposomes linked to HER2/neu‐derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer

  2018cites this paper
• Immune response to human telomerase reverse transcriptase‐derived helper T cell epitopes in hepatocellular carcinoma patients

  2018cites this paper